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ABSTRACT
The Wilms' tumor gene, WT1, encodes transcription factors that regulate cell proliferation, differentiation, and apoptosis. WT1 protein is highly expressed in malignant pleural mesothelioma (MPM), and is a rational target for immunotherapy. We have developed a vaccine comprised of four WT1 heteroclitic peptides that are given together with Montanide and GM-CSF as immunologic adjuvants. This WT1 vaccine was previously tested in a small pilot trial, and shown to be safe and immunogenic.
We have chosen to test the efficacy of this vaccine in MPM patients who have minimal disease burden after completion of multimodality therapy, but remain at exceedingly high risk for recurrence. The specific aim of this project is to conduct a multicenter, blinded, randomized trial comparing treatment with the WT-1 peptide vaccine + Montanide/GM-CSF to treatment with Montanide/GM-CSF alone in patients with MPM who have completed multimodality therapy. The primary endpoint is progression free survival. The trial has opened at Memorial Sloan-Kettering and is actively enrolling patients.
INTRODUCTION:
The Wilms' tumor gene, WT1, encodes transcription factors that regulate cell proliferation, differentiation, and apoptosis. WT1 protein is highly expressed in malignant pleural mesothelioma (MPM), and is a rational target for immunotherapy. We have developed a vaccine comprised of four WT1 heteroclitic peptides that are given together with Montanide and GM-CSF as immunologic adjuvants. This WT1 vaccine was previously tested in a small pilot trial, and shown to be safe and immunogenic. We have chosen to test the efficacy of this vaccine in MPM patients who have minimal disease burden after completion of multimodality therapy, but remain at exceedingly high risk for recurrence. The specific aim of this project is to conduct a multicenter, double-blinded, randomized trial comparing treatment with the WT-1 peptide vaccine + Montanide/GM-CSF to treatment with Montanide/GM-CSF alone in patients with MPM who have completed multimodality therapy. The primary endpoint is progression free survival.
BODY:
This project has proceeded as indicated in the approved Statement of Work:
• The peptides were purchased, manufactured, and underwent sterility testing.
• The peptides were ordered from AmbioPharm, Inc. Once produced, they were vialed under GMP conditions by University of Iowa Pharmaceuticals. The investigational agent completed sterility and stability testing to ensure safety for human use. The vials were delivered to the pharmacy at MSKCC.
• The protocol was reviewed by the various committees at MSKCC and the DOD leading to IRB approval.
• Since IRB approval in September, 2010, the study has received approval from the FDA on 12/21/2010. During that time, the protocol was reviewed by the HRPO at the Department of Defense and several comments were made requiring changes to the protocol. The requested changes were made, reviewed by HRPO, and an amendment to the protocol was submitted to the IRB. The amendment was approved on 2/9/11. Final review took place by HRPO and an approval memo was issued on 2/11/11. • A start-up meeting was held with the research staff on 2/1/11 to inform all of the participants about the rationale, design, and logistics of this study.
• M.D Anderson Cancer Center is in the process of submitting the documents for the institutional review process at their center. Several conference calls have been held with M.D. Anderson to discuss various regulatory issues which seem to have been resolved at this point.
• Additional sites have not yet been recruited for participation in the study due to budget constraints.
KEY RESEARCH ACCOMPLISHMENTS:
• The planned randomized phase II trial is open at MSKCC and is actively accruing patients.
REPORTABLE OUTCOMES:
This protocol was highlighted in several presentations over the last few months which will hopefully increase exposure and ultimately enrollment. This includes: ASCO, Chicago, IL -poster presented at Trials in Progress Session Meso Symposium, Washington DC, slide presentation World Conference on Lung Cancer, Amsterdam, slide presentation
CONCLUSION:
The clinical trial is open to enrollment at Memorial Sloan-Kettering which will continue for the next three years. Efforts continue to open the study at MD Anderson.
